Treatment of Metastatic Colorectal Cancer in the Elderly

Nguyen, Hong Loi; Hwang, Jimmy

doi:10.1007/s11864-009-0111-7

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the fact that society is aging worldwide, treatment opportunities for managing mCRC in elderly patients are expanding. Treatment decisions in elderly patients should be based not only upon age, but also upon ECOG PS, chemotherapy‐related cytotoxicity, and consideration of accompanying comorbidities …”

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic outcomes for metastatic colorectal cancer in elderly patients aged ≥75 years: A single-institutional retrospective analysis

Miguchi

Shimomura

Hinoi

et al. 2016

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

Aim To reveal systemic chemotherapy outcomes and the suitable first‐line regimens for elderly (≥75 years) metastatic colorectal cancer (mCRC) patients. Methods We retrospectively compared systemic chemotherapy outcomes between elderly (≥75 years) and adult (≤74 years) patients with mCRC who were treated between January 2007 and December 2012 at Hiroshima University Hospital and analyzed the outcomes of elderly patients after treatment with single‐agent oral 5‐fluorouracil chemotherapy (oral FC) or intravenous combination chemotherapy (IV CC) as the first‐line regimen. Results A total of 140 patients with mCRC were enrolled. The median age of adult patients was 60 years, compared to 77 years for elderly patients. There were no significant differences between the two groups in terms of patient characteristics and the stage of cancer progression. Overall survival (OS) (median, 20.7 vs 26.5 months; P = 0.65) and first‐line progression‐free survival (PFS) (median, 11.0 vs 9.8 months; P = 0.36) did not differ significantly between elderly patients and adult patients. Among elderly patients, first‐line PFS (median, 10.3 months vs. 11.8 months; P = 0.85) and the incidence of grade 3 adverse events (22.2% vs. 44.4%; P = 0.31) were similar in the oral FC and IV CC groups. Conclusion The results of this study suggest that elderly patients with mCRC who can receive chemotherapy derive an equivalent survival benefit to adult patients. First‐line oral FC may be better suited for elderly patients with mCRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic outcomes for metastatic colorectal cancer in elderly patients aged ≥75 years: A single-institutional retrospective analysis

Miguchi

Shimomura

Hinoi

et al. 2016

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Treatment decisions in older patients should be based upon not only age, but also upon performance status, cytotoxicity of chemotherapeutics, and consideration of accompanying comorbidities (Nguyen et al, 2009). Fit elderly mCRC patients without any chronic disease and organ dysfunction, are appropriate candidates for intensive first-line treatment (Aparicio et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer

Varol

Dirican²,

Yıldız³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Unlike for fit elderly metastatic colorectal cancer (mCRC) patients, general approaches to initial treatment for the frail older mCRC patients are not clear. Our aim was to evaluate the efficiency and safety of first-line single-agent treatment in one such group. Materials and Methods: We retrospectively evaluated mCRC patients aged 70 or older with an Eastern Cooperative Oncology Group performance score of 2. They had no prior treatment and underwent first-line single-agent capecitabine or other monotherapies until disease progression or unacceptable toxicity. Results: Thirty-six patients were included. Most (n:28, 77.8%) were treated with capecitabine. One patient achieved a complete response and 5 patients had a partial response for an overall response rate of 16.6%. Twelve patients (33.3%) remained stable. Median progression free survival was 5 months (confidence interval (CI), %; 3.59-6.40) and median overall survival was 10 months (95 CI%; 8.1-11.8). Grade 3-4 toxicity was found in 6 patients (16.6%). Febrile neutropenia was not observed and there were no toxicity-associated deaths. Conclusions: Capecitabine is a safe chemotherapeutic agent with moderate activity for first-line treatment of older metastatic colorectal cancer patients with limited performance status.

show abstract

Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer

Cartwright¹

2012

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Treatment of Metastatic Colorectal Cancer in the Elderly

Cited by 5 publications

References 33 publications

Chemotherapeutic outcomes for metastatic colorectal cancer in elderly patients aged ≥75 years: A single-institutional retrospective analysis

Chemotherapeutic outcomes for metastatic colorectal cancer in elderly patients aged ≥75 years: A single-institutional retrospective analysis

First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer

Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer

Contact Info

Product

Resources

About